Defand Therapeutics

Based in Hangzhou, China, Defand Therapeutics is a biotechnology company focused on developing innovative therapeutic solutions, particularly in the realm of drug discovery and clinical research. Defand Therapeutics specializes in therapeutic drug development. Founded in 2023 in Hangzhou, China, the company has completed one funding round as of July 18, 2025, securing pre-Series A funding from undisclosed investors. The details of the founder's background are not publicly available.

Defand Therapeutics is dedicated to advancing healthcare by focusing on the development of innovative drugs that address critical medical needs. Their product pipeline includes novel therapeutics designed to target various diseases, utilizing cutting-edge research methodologies to enhance efficacy and safety. The company aims to conduct preclinical and clinical trials to validate these therapeutics and is actively exploring partnerships for further development. Defand Therapeutics generates revenue primarily through the advancement of its drug candidates toward clinical stages, with funding rounds supporting R&D initiatives.

The company is expected to implement financial strategies that may include partnerships and licensing agreements to facilitate the commercialization of its therapeutic solutions. Defand Therapeutics plans to leverage funds from its recent pre-Series A financing, raised in July 2025, to accelerate its research and development efforts. The company aims to bring more innovative drugs into clinical stages, with the goal of launching new therapeutic products in the near future. Additionally, Defand Therapeutics is exploring expansion into international markets, particularly targeting opportunities in Southeast Asia and Europe by 2026.